3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Motor Activity
3
Lymphoma
2
Leukemia, Myeloid, Acute
2
Leukemia
2
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Obesity
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
Cyclophosphamide
85
fludarabine phosphate
84
Peripheral Blood Stem Cell Transplantation
70
Mycophenolic Acid
58
Tacrolimus
57
Whole-Body Irradiation
55
Busulfan
54
Antilymphocyte Serum
47
Cyclosporine
45
Methotrexate
38
fludarabine
37
Filgrastim
37
Melphalan
32
Radiotherapy
27
Cytarabine
27
Etoposide
21
Methylprednisolone
20
Cord Blood Stem Cell Transplantation
18
Azacitidine
18
Sirolimus
15
Granulocyte Colony-Stimulating Factor
15
Flow Cytometry
14
Cyclosporins
14
thymoglobulin
13
Specimen Handling
13
Alemtuzumab
13
Biopsy
12
venetoclax
10
Thiotepa
10
Decitabine
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
Resistance Training
×
Other hematologic neoplasm
×
Clear all
NCT07518940
2026-04-09
ENERGIA
University of Turin, Italy
Phase NA
Not yet recruiting
25 enrolled